Milestone Pharmaceuticals Inc. (MIST)
| Market Cap | 170.12M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -46.14M |
| Shares Out | 29.85M |
| EPS (ttm) | -1.55 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | August 3 |
| Last Price | $5.70 |
| Previous Close | $5.79 |
| Change ($) | -0.09 |
| Change (%) | -1.55% |
| Day's Open | 5.79 |
| Day's Range | 5.52 - 5.99 |
| Day's Volume | 93,875 |
| 52-Week Range | 5.09 - 10.45 |
MONTREAL and CHARLOTTE, N.C., May 26, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardi...
Milestone Pharmaceuticals Inc (NASDAQ: MIST) hit a major snag last March when its investigational etripamil nasal spray for episodes of rapid heart rate missed the primary endpoint. A year later, it's t...
- Statistically Significant Improvements in PSVT-Associated Symptoms and Less ER Visits Observed in Patients Treated with Etripamil Compared to Placebo in the NODE-301 Trial - - Data Presented at the Am...
MONTREAL and CHARLOTTE, N.C., May 17, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardi...
MONTREAL and CHARLOTTE, N.C., May 17, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardi...
If Milestone Pharmaceuticals' Etripamil nasal spray succeeds in clinical trials, MIST stock is going to see big growth. The post Milestone Pharmaceuticals Stock Is a Bet On Etripamil appeared first on I...
MONTREAL and CHARLOTTE, N.C., March 29, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative car...
MONTREAL and CHARLOTTE, N.C., March 29, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative car...
MONTREAL and CHARLOTTE, N.C., Feb. 25, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative card...
MONTREAL and CHARLOTTE, N.C., Nov. 23, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative card...
MONTREAL and CHARLOTTE, N.C., Nov. 13, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative card...
MONTREAL and CHARLOTTE, N.C., Oct. 23, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing ...
MONTREAL and CHARLOTTE, N.C., Oct. 22, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing ...
MONTREAL and CHARLOTTE, N.C., Sept. 22, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative car...
Milestone Pharmaceuticals offers a critical solution for those with an acute heart condition. However, it has a mixture of positives and negatives, making MIST stock a wild wager.
When a biotech firm focuses its efforts on one disease and one drug, the stakes are high. Still, the payoff could be huge with MIST stock.
MONTREAL and CHARLOTTE, N.C., Aug. 12, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals (MIST) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Milestone Pharmaceuticals (MIST) news for Thursday includes new guidelines for a clinical study pushing MIST stock higher.
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) shares more than doubled on Thursday after the company announced a key clinical and regulatory update.
MONTREAL and CHARLOTTE, N.C., July 23, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc.
As of late, it has definitely been a great time to be an investor in Milestone Pharmaceuticals.
Milestone Pharmaceuticals (MIST) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
As of late, it has definitely been a great time to be an investor of Milestone Pharmaceuticals
Top Ranked Momentum Stocks to Buy for May 19th
MONTREAL and CHARLOTTE, N.C., May 14, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardi...
Milestone Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Here we provide three stocks from the drug and biotech sector which can offer protection to an investor's portfolio amid stock market turmoil due to coronavirus crisis.
Shares of small-cap Milestone Pharmaceuticals Inc (NASDAQ: MIST) were losing three-quarters of their value Tuesday on the back of a negative clinical readout.
Soon-to-be-released pivotal clinical trial results could send this drug developer’s stock skyward.
About MIST
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. It is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as in the Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate, and other cardiovascular indications. Milestone Pharmaceuticals Inc. has a license and collaboration agreement with ... [Read more...]
| Industry Biotechnology | Founded 2003 |
| Stock Exchange NASDAQ | Ticker Symbol MIST |
Analyst Forecasts
According to 4 analysts, the average rating for MIST stock is "Buy." The 12-month stock price forecast is 13.80, which is an increase of 142.11% from the latest price.